
We look at a COVID-19 remedy called monoclonal antibodies—or MAB for short. They are basically antibodies made in a lab and they can potentially be life-saving. But this treatment is in short supply in many areas in the U.S. including but not limited to Connecticut, Nevada, and Ohio. NTD spoke with CEO Michael Einhorn who runs Dealmed. He says there are a lot of reasons for the shortage of MABs, but he says government intervention is a main driver.












Very few private individuals have had a bigger impact on the global fight against the Covid pandemic than Bill Gates. Through the work of his foundation, the tech billionaire is a major player. What he has to say on the issue is worth our 
